Uma Borate, MD

Dr. Uma Borate, a leukemia treatment expert from The Ohio State University, joins the hosts for an insightful discussion on breakthroughs from ASH 2024. They delve into the promising KOMET 007 study on the Menin inhibitor Ziftomenib, noting its effectiveness for patients with specific genetic mutations. The conversation shifts to the comparison between CPX351 and traditional 7+3 induction therapies, revealing key insights about response rates. Additionally, they explore the role of Venetoclax in treating patients without actionable mutations, emphasizing NGS testing's vital role in targeted therapies.

Experts Uma Borate, Kelly Bolton, and Eric Padron discuss the early stages of blood disorders, CHIP, and CCUS, emphasizing the importance of multidisciplinary teamwork. They cover topics such as blood cancer risk assessment, diagnostic challenges, bone marrow biopsies, and the connection between clonal hematopoiesis patients and cardiovascular diseases.